The Alzheimer's Drug Discovery Foundation (ADDF) is a 501(c)(3) nonprofit organization based in Midtown Manhattan at 57 West 57th Street, Suite 904, New York, NY 10019. The organization was established in 2005 (formerly known as the Institute for the Study of Aging) and is dedicated to rapidly accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease and related dementias. The ADDF employs a venture philanthropy model to support research in both academia and the biotech industry.
Financial Overview
From 2024 IRS Form 990-PF · View filing
Total Assets
$299.4M
-7.6% YoY
Annual Giving
$54.8M
+53.6% YoY
Grant Count
26
+0.0% YoY
Avg Grant Size
$2.1M
+53.6% YoY
Mission & Focus Areas
Mission: Accelerate the discovery of drugs to prevent, treat and cure Alzheimer's disease and related dementias.
The ADDF is solely focused on funding the development of drugs for Alzheimer's and related dementias. The organization's work encompasses multiple research areas including:
- Drug development and therapeutics
- Diagnostics acceleration and precision medicine
- Biomarker research and clinical trials
- Neuroimaging and cerebrospinal fluid (CSF) biomarker programs
- Prevention research
- Frontotemporal degeneration drug discovery
- Digital biomarkers programs
Grantmaking
The ADDF maintains an active grantmaking portfolio with multiple funding opportunities available to researchers and biotech companies.
How to Apply
**
Ready to take the next step with Alzheimer's Drug Discovery Foundation?
Geographic Focus
Where this funder awards grants
The ADDF funds research primarily in New York, Massachusetts, and California, with a global scope supporting Alzheimer's research worldwide.
Grant Distribution by State
States
Cities
Financial History
Multi-year comparison from IRS filings
Fiscal Year 2024:
- Revenue: $47.3 million
- Expenses: $88.3 million
- Total Assets: $299 million
- Total Liabilities: $82.4 million
Tax Status: Tax-exempt since September 2005 (EIN: 20-1082179)
Rating: Four-Star Charity with a 100% score from independent evaluators, reflecting strong accountability and financial practices.
The organization publishes comprehensive annual reports and audited financial statements available for fiscal years 2019 through 2025.
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Total Assets | $299,394,693 | $324,173,528 | $340,253,841 |
| Revenue | $47,282,987 | $37,742,020 | $254,027,105 |
| Expenses | $88,250,427 | $61,943,588 | $36,842,901 |
| Qualifying Distributions | — | — | — |
| Net Investment Income | $5,534,433 | $3,119,933 | $-2,054,312 |
| Distributable Amount | — | — | — |
Giving Over Time
Total grant dollars and number of grants per year
Grant Insights
How this funder distributes its grants
Top Recipients
Top 10 recipients in 2024
Grant Size Distribution
128 grants across all recorded years
Open Grants
7 open opportunities from Alzheimer's Drug Discovery Foundation
ADDF-Harrington Scholar Program Grant
ALZHEIMER'S DRUG DISCOVERY FOUNDATION
Amount
Up to US $600,000
Deadline
Rolling / Open
Conference Funding
ALZHEIMER'S DRUG DISCOVERY FOUNDATION
Amount
Varies
Deadline
Rolling / Open
Diagnostics Accelerator: Digital Biomarkers Program Grant
ALZHEIMER'S DRUG DISCOVERY FOUNDATION
Amount
Varies
Deadline
Rolling / Open
Giving History
Grant recipients and amounts by year
No grants recorded for .
Leadership & Key People
Leadership team and compensation from IRS filings
Chief Executive Officer: Isobel Coleman (appointed to lead the next era of Alzheimer's breakthroughs)
Science & Media Contact: Available for interviews and includes experts in Alzheimer's disease, dementia prevention, and drug discovery and development (media@alzdiscovery.org)
Donor Support Contact: Allison Ruttley (aruttley@alzdiscovery.org, 929-642-0339)
Compensation Overview
From 2024 IRS filing
From 2024 filing
| Name | Title | Hours | Compensation |
|---|---|---|---|
| ADAM HOFFMAN | GOVERNOR | 1 | — |
| ALICE SHURE | GOVERNOR | 1 | — |
| ANN JACKSON | GOVERNOR | 1 | — |
| BONNIE ENGLEBARDT LAUTENBERG | GOVERNOR | 1 | — |
| BONNIE PFEIFER EVANS | GOVERNOR | 1 | — |
| CAROL BOULANGER | GOVERNOR | 1 | — |
| DAVID WEINREB | GOVERNOR | 1 | — |
| GARY M LAUDER | GOVERNOR | 1 | — |
| HENRIK ZETTERBERG MD PHD | GOVERNOR | 1 | — |
| HOWARD FILLIT MD | FOUNDING EXEC. DIR. & CHIEF SCIENCE OFF. | 40 | $663,174 |
| JULIEANN SHANAHAN CFA | GOVERNOR | 1 | — |
| LANNY EDELSOHN MD | GOVERNOR | 1 | — |
| LAURA STEELE | GOVERNOR | 1 | — |
| LAURENCE LEEDS JR | GOVERNOR | 1 | — |
| LEONARD LAUDER | CO-CHAIRMAN /GOVERNOR (DECEASED) | 1 | — |
| MIIA KIVIPELTO MD PHD | GOVERNOR | 1 | — |
| NANCY CORZINE | GOVERNOR | 1 | — |
| NANCY GOODES | GOVERNOR | 1 | — |
| NIRANJAN BOSE PHD | GOVERNOR | 1 | — |
| PAULA ZAHN | GOVERNOR | 1 | — |
| PHILIP SCHELTENS MD PHD | GOVERNOR | 1 | — |
| RACHID IZZAR | GOVERNOR | 1 | — |
| RANDAL SANDLER | CO-VICE CHAIRMAN & SECRETARY | 1 | — |
| RIC EDELMAN | GOVERNOR | 1 | — |
| RICHARD MOHS PHD | GOVERNOR | 1 | — |
| ROBERTA DIAZ BRINTON PHD | GOVERNOR | 1 | — |
| RONALD LAUDER | CO-CHAIRMAN /GOVERNOR | 1 | — |
| SHARON SAGER | GOVERNOR | 1 | — |
| THOMAS MCWILLIAMS | CO-VICE CHAIRMAN & TREASURER | 1 | — |
| THOMAS SMITH JR | GOVERNOR | 1 | — |
| KAREN HARRIS | CFO AND HEAD OF MISSION RELATED INV | 40 | $369,039 |
| MARK ROITHMAYR | CEO | 40 | $651,120 |
| AARON BURSTEIN | HEAD OF SEARCH AND EVALUATION | 40 | $314,231 |
| ELI SHOBIN | SENIOR DIRECTOR DXA | 40 | $235,962 |
| JANE MCINTOSH | CHIEF EXTERNAL AFFAIRS | 40 | $377,792 |
| LAKITA CAVIN | ATTORNEY, MISSION-RELATED | 40 | $220,246 |
| LAURA NISENBAUM | EXECUTIVE DIRECTOR, DRUG DEVELOPMENT | 40 | $442,772 |
Recent News & Activity
Recent developments and announcements
**Diagnostics Accelerator Expansion:** ADDF launched a new phase of the Diagnostics Accelerator, powering the next generation of Alzheimer's precision medicine worldwide
**Leadership Appointment:** Isobel Coleman appointed as Chief Executive Officer to lead the next era of Alzheimer's breakthroughs
**Biomarker Research:** ADDF published a landmark Biomarker Observatory paper offering the first comprehensive view of biomarker use across Alzheimer's clinical trials
Latest Funding Includes Support for Innovative Clinical Trial | Alzheimer's**2026 Melvin R. Goodes Prize:** Awarded to Alzheimer's research pioneer Randall J. Bateman, MD
**Semaglutide Research:** New semaglutide data offers key insights for next generation Alzheimer's therapies
**FDA Approval:** Leqembi received first FDA approval for subcutaneous formulation for Alzheimer's
**Fundraising Campaign:** Milestones in Motion campaign underway to support the most promising Alzheimer's research around the world
Latest Funding Includes Support for Innovative Clinical Trial | Alzheimer'sContact Information
Main Office:
- Address: 57 West 57th Street, Suite 904, New York, NY 10019
- Phone: 212.901.8000
- Email: info@alzdiscovery.org
Media Inquiries: media@alzdiscovery.org
Website: www.alzdiscovery.org
Subject Areas
Focus areas based on grantmaking activity
Related Funders
Similar funders by location and focus area
Launa Beuhler Foundation for
BROOKLYN, NY
Assets
$2K
Grants
4
Total Given
$20K
Uw E J Madden Mem Open Hearts Club 10-214880
NEW YORK, NY
Assets
$1.3M
Grants
1
Total Given
$307K
Hindy's Foundation
BROOKLYN, NY
Assets
$142K
Grants
8
Total Given
$225K
Jeanne & Thomas Hardy Family Foundation
NEW YORK, NY
Assets
$3K
Grants
3
Total Given
$3K
Ramsleg Foundation
BRIGHTWATERS, NY
Assets
$543
Grants
1
Total Given
$500
Druckenmiller Foundation
NEW YORK, NY
Assets
$1.8B
Grants
58
Total Given
$135.7M
Data last updated April 2026. Sourced from IRS Form 990-PF filings. Research dossier generated April 2026.
What could you do with Alzheimer's Drug Discovery Foundation on Grantable?
- Assess strategic fit with your organization
- Draft a tailored letter of inquiry
- Find open RFPs from this funder
- Monitor for new funding opportunities